CAH Cardinal Health
Toll-booth oligopolist on US drug flow; specialty mix nudges thin margins up, priced near fair value.
The story
Cardinal Health is one of three US drug-distribution oligopolists alongside McKesson and Cencora. It moves about $250B of pharmaceuticals at razor-thin margins, but because the business runs on negative working capital it earns very high returns on capital. It is a mature franchise with a scale moat. Growth comes from GLP-1 and specialty volumes, oncology and MSO platforms, and higher-margin Optum/at-Home and Nuclear segments, while the Global Medical Products segment is a turnaround.
Reported margins of about 1% are depressed by opioid litigation and GMPS charges. The underlying adjusted margin is around 1.3% and is rising with the specialty mix, so I converge to 1.4% rather than lock in the trough GAAP figure. Sales-to-capital is trimmed from 42 to 30 to cover acquisitions such as the specialty MSO roll-ups. Near-term growth tracks the specialty and GLP-1 tailwinds and then fades to a nominal-GDP-like 3%.
Value drivers
| Revenue growth (Y1) | 9.0% |
| Terminal growth | 3.0% |
| Forecast horizon | 8y |
| Target operating margin | 1.4% |
| Years to target margin | 4 |
| Sales-to-capital | 6.00 |
| Beta | 0.90 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 8.7% |
| Terminal WACC | 9.1% |
Valuation bridge
| PV of explicit FCFF | 1.44B |
| PV of terminal value | 30.65B |
| Equity value | 27.35B |
| ÷ shares → per share | $118.10 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 277.13B | 9.0% | 1.1% | 2.38B | 3.81B | -1.44B | -1.32B |
| 2 | 299.70B | 8.1% | 1.2% | 2.81B | 3.76B | -950.01M | -803.48M |
| 3 | 321.53B | 7.3% | 1.3% | 3.27B | 3.64B | -366.08M | -284.73M |
| 4 | 342.20B | 6.4% | 1.4% | 3.76B | 3.44B | 312.31M | 223.40M |
| 5 | 361.27B | 5.6% | 1.4% | 3.97B | 3.18B | 789.04M | 519.05M |
| 6 | 378.30B | 4.7% | 1.4% | 4.15B | 2.84B | 1.32B | 795.60M |
| 7 | 392.89B | 3.9% | 1.4% | 4.31B | 2.43B | 1.88B | 1.05B |
| 8 | 404.68B | 3.0% | 1.4% | 4.44B | 1.96B | 2.48B | 1.27B |
Key risks
- Drug pricing reform (IRA negotiation, PBM/340B changes) compresses distributor economics
- Customer concentration: loss or repricing of a major account like the CVS/OptumRx type contracts
- GLP-1 volume is low-margin and could shift to direct-to-consumer channels; ongoing opioid settlement payments
Catalysts
- Specialty/MSO platform growth and continued upward EPS guidance revisions
- GMPS margin recovery and potential separation of medical products